Systemic inflammatory responses to surgery with cardiopulmonary bypass

Perfusion

Volumn 11, Issue 3, 1996, Pages 177-189

  Royston, D ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; HOST RESISTANCE; HUMAN; INFLAMMATION; ISCHEMIA; LEUKOCYTE ACTIVATION; OPEN HEART SURGERY; PRIORITY JOURNAL; REPERFUSION; THROMBOCYTE ACTIVATION; TIME; TISSUE INJURY;

EID: 0029847255     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765919601100302     Document Type: Conference Paper

References (81)

1. Edmunds L Jr. Blood-surface interactions during cardiopulmonary bypass. J Cardiac Surg 1993; 8: 404-10.
2. Royston D. Blood cell activation. Semin Thorac Cardiovasc Surg 1990; 2: 341-57.
3. Royston D, Minty B, Wallwork J, Higenbottam T, Jones J. The effects of surgery with cardiopulmonary bypass on alveolar-capillary barrier function in man. Ann Thorac Surg 1985; 40: 133-42.
4. Tsiotos GG, Mullany CJ, Zietlow S, van-Heerden JA. Abdominal complications following cardiac surgery. Am J Surg 1994; 167: 553-57.
5. Nussmeier NA. Neuropsychiatric complications of cardiac surgery. J Cardiothorac Vasc Anesth 1994; 8: 13-18.
6. Hennein HA, Ebba H, Rodriguez JL et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994; 108: 626-35.
7. Iwanaga S, Muta T, Shigenaga T et al. Role of hemocyte-derived granular components in invertebrate defense. Ann NY Acad Sci 1994; 712: 102-16.
8. Muta T, Oda T, Iwanaga S. Horseshoe crab coagulation factor B. A unique serine protease zymogen activated by cleavage of an Ile-Ile bond. J Biol Chem 1993; 268: 21384-88.
9. Muta T, Tokunaga F, Nakamura T, Morita T, Iwanaga S. Limulus clotting factor C: lipopolysaccharide-sensitive serine protease zymogen. Methods Enzymol 1993; 223: 336-45.
10. Tapparelli C, Metternich R, Ehrhardt C, Cook NS. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. Trends Pharmacol Sci 1993; 14: 366-76.
11. Fareed J, Hoppensteadt D, Walenga JM, Bick RL. Current trends in the development of anticoagulant and antithrombotic drugs. Med Clin North Am 1994; 78: 713-31.
12. Colman RW, Mattler L, Sherry S. Studies on the prekallikrein (kallikreinogen)-kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. J Clin Invest 1969; 48: 23-32.
13. Colman RW, Mattler L, Sherry S. Studies on the prekallikrein (kallikreinogen)-kallikrein enzyme system of human plasma. I. Isolation of purification of plasma kallikreins. J. Clin Invest 1969; 48: 11-22.
14. Wachtfogel YT, Kucich U, Hack CE et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106: 1-9.
15. Wiggins RC, Giclas PC, Henson PM. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J Exp Med 1981; 153: 1391-404.
16. Ward PA. A plasmin-split fragment of C′3 as a new chemotactic factor. J Exp Med 1967, 126: 189-206, Issn: 0022-1007.
17. Boisclair MD, Lane DA, Philippou H et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993; 82: 3350-57.
18. Burman JF, Chung HI, Lane DA, Philippou H, Adami A, Lincoln JCR. Role of Factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet 1994; 344: 1192-93.
19. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981; 304: 497-503.
20. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86: 845-57.
21. Westaby S. Complement and the damaging effects of cardiopulmonary bypass [editorial]. Thorax 1983; 38: 321-25.
22. Weinberg PF, Matthay MA, Weslen O, Roskos KV, Godstein TM, Murray JF. Biologically active products of complement and acute lung injury in patients with the sepsis syndrome. Am Rev Respir Dis 1984; 130: 791-96.
23. Gillinov AM, Redmond JM, Winkelstein JA et al. Complement and neutrophil activation during cardiopulmonary bypass: a study in the complement-deficient dog. Ann Thorac Surg 1994; 57: 345-52.
24. Homeister JW, Satoh P, Lucchesi BR. Effects of complement activation in the isolated heart. Role of the terminal complement components. Circ Res 1992; 71: 303-19.
25. Utley JR. Pathophysiology of cardiopulmonary bypass: current issues. J Cardiac Surg 1990; 5: 177-89.
26. Sundaram S, Courtney JM, Taggart DP et al. Biocompatibility of cardiopulmonary bypass: influence on blood compatibility of device type, mode of blood flow and duration of application. Int J Artif Organs 1994; 17: 118-28.
27. Nilsson L, Tyden H, Johansson O et al. Bubble and membrane oxygenators-comparison of postoperative organ dysfunction with special reference to inflammatory activity. Scand J Thorac Cardiovasc Surg 1990; 24: 59-64.
28. Salzman EW, Merrill EW, Binder A, Wolf CF, Ashford TP, Austen WG. Protein-platelet interaction on heparinized surfaces. J Biomed Mater Res 1969; 3: 69-81.
29. Gluszko P, Rucinski B, Musial J et al. Fibrinogen receptors in platelet adhesion to surfaces of extracorporeal circuit. Am J Physiol 1987; 252: H615-21.
30. Musial J, Niewiarowski S, Hershock D, Morinelli TA, Colman RW, Edmunds LH Jr. Loss of fibrinogen receptors from the platelet surface during simulated extracorporeal circulation. J Lab Clin Med 1985; 105: 514-22.
31. Harker LA. Bleeding after cardiopulmonary bypass [Editorial]. N Engl J Med 1986; 314: 1446-18.
32. Zilla P, Fasol R, Groscurth P, Klepetko W, Reichenspurner H, Wolner E. Blood platelets in cardiopulmonary bypass operations. Recovery occurs after initial stimulation, rather than continual activation. J Thorac Cardiovasc Surg 1989; 97: 379-88.
33. Fidlar E, Jaques L. The effects of commercial heparin on the platelet count. J Lab Clin Med 1948; 33: 1410.
34. Warkentin TE, Kelton JG. Heparin and platelets. Hematol Oncol Clin North Am 1990; 4: 243-64.
35. Fish KJ, Sarnquist FH, van Steennis C et al. A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations. J Thorac Cardiovasc Surg 1986; 91: 436-12.
36. Davis R, Whittington R. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 1995; 49: 954-83.
37. Murase M, Usui A, Tomita Y, Maeda M, Koyama T, Abe T. Nafamostat mesylate reduces blood loss during open heart surgery. Circulation 1993; 88: 432-36.
38. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth 1992; 6: 76-100.
39. Wildevuur CR, Eijsman L, Roozendaal KJ, Harder MP, Chang M, van Oeveren W. Platelet preservation during cardiopulmonary bypass with aprotinin. Eur J Cardiothorac Surg 1989; 3: 533-37.
40. Lu H, Soria C, Soria J et al. Reversible translocation of glycoprotein Ib in plasmin-treated platelets: consequences for platelet function. Eur J Clin Invest 1993; 23: 785-93.
41. Orchard MA, Goodchild CS Prentice CR et al. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 1993; 85: 533-41.
42. Ketterl R, Haas S, Lechner F, Kienzle H, Blumel G. [Effect of aprotinin on thrombocytic function during total endoprosthesis surgery of the hip]. Med Welt 1980; 31: 1239-43.
43. Ketterl R, Haas S, Heiss A et al. [Effect of the natural proteinase inhibitor aprotinin on platelet function in allo-arthroplastic hip replacement]. Med Welt 1982; 33: 480-86.
44. Haas S, Ketterl R, Stemberger A et al. The effect of aprotinin on platelet function, blood coagulation and blood lactate level in total hip replacement - a double blind clinical trial. Adv Exp Med Biol 1984; 167: 287-97.
45. Haas S, Müller-Esterl W, Fritsche H-M et al. Effect of aprotinin on the incidence of thrombosis and postoperative bleeding. Thromb Haemostasis 1985; 54: 587: Abstract 99.
46. Royston BD, Royston D, Pearson JD. Aprotinin inhibits platelet adhesion to endothelial cells. Blood Coagul Fibrinolysis 1992; 3: 737-42.
47. Royston BD, Royston D, Coade SB, Morgan DM, Pearson JD. Aprotinin does not inhibit the release of PGI2 or vWF from cultured human endothelial cells. Thromb Haemost 1992; 67: 172-75.
48. Soslau G, Horrow J, Brodsky I. Effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hematol 1991; 38: 113-19.
49. Boldt J, Schindler E, Osmer C, Wittstock M, Stertmann WA, Hempelmann G. Influence of different anticoagulation regimens on platelet function during cardiac surgery. Br J Anaesth 1994; 73: 639-44.
50. Lu H, Soria C, Commin PL et al. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemost 1991; 66: 633-37.
51. Lazenby WD, Russo I, Zadeh BJ et al. Treatment with desmopressin acetate in routine coronary artery bypass surgery to improve postoperative hemostasis. Circulation 1990; 82: IV413-19.
52. Andersson TL, Solem JO, Tengborn L, Vinge E. Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation. Circulation 1990; 81: 872-78.
53. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 958-67.
54. Blauhut B, Harringer W, Bettelheim P, Doran JE, Spath P, Lundsgaard Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 108: 1083-91, Issn: 0022-5223.
55. Freise J, Witenberg H, Magerstedt P. In vitro inhibition of phospholipase A2 by gabexate mesilate, camostate, and aprotinine. Klin Wochenschr 1989; 67: 149-52.
56. Nagaoka H, Innami R, Murayama F et al. Effects of aprotinin on prostaglandin metabolism and platelet function in open heart surgery. J Cardiovasc Surg Torino 1991; 32: 31-37.
57. Gillinov AM, Bator JM, Zehr KJ et al. Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenators. Ann Thorac Surg 1993; 56: 847-53.
58. Royston D, Fleming JS, Desai JB, Westaby S, Taylor KM. Increased production of peroxidation products associated with cardiac operations. Evidence for free radical generation. J Thorac Cardiovasc Surg 1986; 91: 759-66.
59. Menasche P, Piwnica A. Free radicals and myocardial protection: a surgical viewpoint. Ann Thorac Surg 1989; 47: 939-45.
60. Menasche P, Antebi H, Alcindor LG et al. Iron chelation by deferoxamine inhibits lipid peroxidation during cardiopulmonary bypass in humans. Circulation 1990; 82: IV390-96.
61. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Aprotinin in cardiopulmonary bypass-effects on the Hageman factor (FXII)-Kallikrein system and blood loss. Blood Coagul Fibrinolysis 1992; 3: 99-104.
62. Heller W, Fuhrer G, Gallimore MJ, Michel J, Hoffmeister HE. Changes in the kallikreinkinin-system after different dose regimen of aprotinin during cardiopulmonary bypass operation. Adv Exp Med Biol 1989; 247b: 43-48.
63. Faymonville ME, Pincemail J, Duchateau J et al. Myeloperoxidase and elastase as markers of leukocyte activation during cardiopulmonary bypass in humans. J Thorac Cardiovasc Surg 1991; 102: 309-17.
64. Mair P, Mair J, Seibt I, Furtwaengler W, Balogh D, Puschendorf B. Plasma elastase concentrations and pulmonary function after cardiopulmonary bypass [Letter]. J Thorac Cardiovasc Surg 1994; 108: 184-85.
65. Steinberg JB, Kapelanski DP, Olson JHD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 106:P 1008-16.
66. Haeffner-Cavaillon N, Roussellier N, Ponzio O et al. Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989; 98: 1100-106.
67. Stahl RF, Fisher CA, Kucich U et al. Effects of simulated extracorporeal circulation on human leukocyte elastase release, superoxide generation, and procoagulant activity. J Thorac Cardiovasc Surg 1991; 101: 230-39.
68. Gurevitch J, Paz Y, Barak J et al. Role of protease inhibition in myocardial preservation following ischemia and reperfusion. J Cardiovasc Surg Torino 1994; 35: 95-98.
69. Sunamori M, Innami R, Amano J, Suzuki A, Harrison CE. Role of protease inhibition in myocardial preservation in prolonged hypothermic cardioplegia followed by reperfusion. Effect of aprotinin in an experimental model. J Thorac Cardiovasc Surg 1988; 96: 314-20.
70. Coghlan JG, Flitter WD Clutton SM et al. Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994; 107: 248-56.
71. Welbourn R, Goldman G, O'Riordain M et al. Role for tumor necrosis factor as mediator of lung injury following lower torso ischemia. J Appl Physiol 1991; 70: 2645-49.
72. Welbourn CR, Goldman G, Paterson IS, Valeri CR, Shepro D, Hechtman HB. Neutrophil elastase and oxygen radicals: synergism in lung injury after hindlimb ischemia. Am J Physiol 1991; 260: H1852-56.
73. Lindsay TF, Hill J, Ortiz F et al. Blockade of complement activation prevents local and pulmonary albumin leak after lower torso ischemia-reperfusion. Ann Surg 1992; 216: 677-83.
74. Gadaleta D, Fantini GA, Silane MF, Davis JM. Leukotriene generation and pulmonary dysfunction following aortic cross clamp in humans. Ann NY Acad Sci 1994; 723: 470-72.
75. Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions. Transfusion 1993; 33: 195-99.
76. Muylle L, Peetermans ME. Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates. Vox Sang 1994; 66: 14-17.
77. Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. Transfusion 1994; 34: 20-25.
78. Connall TP, Zhang J, Vaziri ND, Kaupke CJ, Wilson SE. Leukocyte CD11b and CD18 expression are increased in blood salvaged for autotransfusion. Am Surg 1994; 60: 797-800.
79. Arnestad JP, Bengtsson A, Bengtson JP, Tylman M, Redl H, Schlag G. Formation of cytokines by retransfusion of shed whole blood. Br J Anaesth 1994; 72: 422-25.
80. de Haan J, Boonstra PW, Monnink SH, Ebels T, van Oeveren W. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. Ann Thorac Surg 1995; 59: 901-907.
81. Hannes W, Keilich M, Koster W, Seitelberger R, Fasol R. Shed blood autotransfusion influences ischemia-sensitive laboratory parameters after coronary operations. Ann Thorac Surg 1994; 57: 1289-94.